<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (MCI) is an etiologically unclear disorder </plain></SENT>
<SENT sid="1" pm="."><plain>Cerebrospinal fluid (CSF) biomarkers are potentially useful for the differentiation between various MCI etiologies </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: The aim of the study was to assess whether baseline CSF hyperphosphorylated tau (P-tau), total tau (T-tau), amyloid beta 1-42 (Abeta(42)) and neurofilament light (NF-L) in patients with MCI could predict subcortical vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e>) and <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) at follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Biomarker levels were assessed by Luminex xMAP technology and ELISA </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Increased baseline concentrations of NF-L significantly separated MCI-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> from stable MCI </plain></SENT>
<SENT sid="5" pm="."><plain>The MCI-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> patients were inseparable from stable MCI but separable from patients developing AD (MCI-AD) on the basis of Abeta(42,) T-tau and P-tau(181) levels </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: A combination of the biomarkers Abeta(42), T-tau, P-tau(181) and NF-L has the potential to improve the clinical separation of MCI-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVD</z:e> patients from stable MCI and MCI-AD patients </plain></SENT>
</text></document>